Q1: Earnings Abstract as of Might 15, 2026
EPS -$0.61 $0.07 Miss
|Income $22.68 million (184.47% YoY) Over $565.00K
Ars Prescription drugs Co., Ltd. (spy) 2026 First Quarter Monetary Report Might 15, 2026 8:30pm EDT
Collaborating corporations
Justin Chakma – Chief Enterprise Officer
Richard Lowenthal – Co-founder, President, CEO and Director
Eric Karas – Chief Industrial Officer
Kathleen Scott – Chief Monetary Officer
Convention name members
Roanna Clarissa Lewis – Leerink Companions LLC, Analysis Division
Lachlan Hanbury-Brown – William Blair & Firm LLC, Analysis Division
Ryan Deschner – Raymond James & Associates, Inc. Analysis Division
Joshua Schimmer – Cantor Fitzgerald & Co, Analysis Division
presentation
operator
good morning. Welcome to the ARS Prescription drugs Q1 2026 Earnings Convention Name. [Operator Instructions] Please be aware that in the present day’s assembly is being recorded. I flip the decision over to Justin Chakma, Chief Enterprise Officer. Please proceed.
Justin Chakma
chief government officer
good morning. Thanks for becoming a member of us for our Q1 2026 Earnings Convention Name. Becoming a member of me on the decision is our co-founder, president and CEO, Richard Lowenthal. Eric Karas, our Chief Industrial Officer. and Kathy Scott, our Chief Monetary Officer. Early this morning, the corporate issued a press launch detailing its monetary outcomes and industrial highlights for the primary quarter of 2026.
The press launch and slide presentation can be found on the Traders and Media part of our web site. Earlier than we start, please be aware that in the present day’s statements might include forward-looking statements. Precise outcomes might differ considerably. Please see our press releases and SEC filings for extra danger disclosures.
Now swap your telephone to wealthy.
richard lowenthal
Co-founder, President, CEO and Director
Thanks, Justin, and good morning everybody, and thanks for becoming a member of us on the decision. After our first full yr as a industrial firm, we’re gaining momentum throughout our enterprise and look ahead to a powerful begin to 2026. In the course of the quarter, we continued to give attention to increasing entry, a key driver of development, and additional rising neffy.
